bellerophon
present
results
phase
study
treatment
fibrotic
interstitial
lung
disease
upcoming
scientific
conferences
warren
globe
newswire
bellerophon
therapeutics
nasdaq
blph
bellerophon
company
biotherapeutics
company
focused
developing
treatments
cardiopulmonary
infectious
diseases
announced
today
data
phase
randomized
clinical
study
treatment
fibrotic
interstitial
lung
disease
patients
risk
pulmonary
hypertension
presented
american
thoracic
society
interstitial
lung
disease
mini
symposia
pulmonary
fibrosis
foundation
meeting
details
presentations
american
thoracic
society
mini
symposia
title
randomized
study
assess
safety
efficacy
pulsed
inhaled
nitric
oxide
ino
subjects
risk
pulmonary
hypertension
ph
associated
fibrotic
interstitial
lung
disease
fild
long
term
oxygen
therapy
presenter
steven
nathan
inova
fairfax
hospital
session
interstitial
lung
disease
biomarkers
treatment
date
time
thursday
november
pm
et
registration
https
meeting
register
pulmonary
fibrosis
foundation
volunteer
meeting
title
pulsed
outpatient
inhaled
nitric
oxide
via
patients
pulmonary
fibrosis
presenter
wassim
fares
chief
medical
officer
bellerophon
therapeutics
plenary
session
updates
pff
clinical
trial
innovation
series
part
date
time
thursday
november
pm
pm
et
weblink
https
docs
bellerophon
bellerophon
therapeutics
biotherapeutics
company
focused
developing
innovative
therapies
address
significant
unmet
medical
needs
treatment
cardiopulmonary
infectious
diseases
company
currently
developing
multiple
product
candidates
program
proprietary
pulsatile
nitric
oxide
delivery
system
information
please
visit
statements
statements
press
release
bellerophon
future
expectations
plans
prospects
including
statements
clinical
development
product
candidates
regulatory
actions
respect
company
clinical
trials
expectations
regarding
sufficiency
company
cash
balance
fund
clinical
trials
operating
expenses
capital
expenditures
statements
containing
words
anticipate
believe
continue
contemplate
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
constitute
statements
within
meaning
private
securities
litigation
reform
act
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
uncertainties
inherent
initiation
future
clinical
trials
availability
timing
data
ongoing
future
clinical
trials
results
trials
whether
preliminary
interim
results
clinical
trial
predictive
final
results
trial
whether
results
early
clinical
trials
indicative
results
later
clinical
trials
expectations
regulatory
approvals
fda
substantial
discretion
approval
process
availability
funding
sufficient
foreseeable
unforeseeable
operating
expenses
capital
expenditure
requirements
factors
discussed
risk
factors
section
company
recent
annual
report
form
subsequent
filings
securities
exchange
commission
addition
statements
included
press
release
represent
bellerophon
views
date
release
relied
upon
representing
company
views
subsequent
date
company
specifically
disclaims
obligation
update
statements
included
press
release
contacts
group
lifesci
advisors
julie
normart
brian
ritchie
jnormart
britchie
